Helicase Venture

Helicase sources through its membership in the Biotechnology Innovation Organization (BIO) investor network, which provides access to vetted therapeutic and life-science startups emerging from US research hubs. Its Boston location at 1 Beacon Street places it within direct reach of Harvard and MIT spinouts. The firm's relationship with Hi-Clearance Inc. also creates a reverse-sourcing channel: Asian medical distributors identify unmet clinical needs that inform US scouting priorities.

Hi-Clearance Inc. is a Taiwanese medical distribution company chaired by John Lee, who also serves as Director at Helicase. The two entities share leadership and strategic alignment: Helicase's early-stage investments in therapeutics and devices gain a potential commercial partner in Hi-Clearance, which distributes medical products throughout Taiwan's hospital systems. This creates an integrated pipeline from US FDA approval to Asian market access.

Helicase concentrates on healthcare services and digital health, with additional exposure to industrial technology and the energy transition. Its strategy emphasizes early-stage companies that can benefit from cross-border scaling between US innovation centers and Asian commercial networks. The firm does not publicly disclose explicit sector exclusions, but its portfolio and affiliated operations center on regulated industries where distribution partnerships create durable advantages.